Quest Diagnostics Incorporated
NYSE:DGXMedical - Diagnostics & Research
-$3.41 today
- Market cap
- $28.57B
- Beta
- 0.59
- P/E (TTM)
- 20.9
- EPS (TTM)
- $9.31
- Dividend yield
- 1.68%
Volume 1.30M
Average 0.91M
DGX Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Quest Diagnostics IncorporatedNYSE: DGX
Common Stock · Q3 FY2026 · quarter ended Sep 2026
Common stock broadly unchanged from a year ago
Common stock stood at $2M at the end of Q3 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Common stock increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 2M USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +0.0%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2M | +0.0% |
| FY2024 | 2024-12-31 | 2M | +0.0% |
| FY2023 | 2023-12-31 | 2M | +0.0% |
| FY2022 | 2022-12-31 | 2M | +0.0% |
| FY2021 | 2021-12-31 | 2M | — |
Common Stock vs competitors
How DGX compares with its peers on the latest reported figures
- DGX's Sep 2026 common stock of $2M is the 4th highest of the 9 companies compared; the peer median is $1.02M.
- Its year-over-year change of +0.0% is the 2nd highest of 9, against a peer median of +0.0%.
- Common stock amounts to 0.0% of total assets for DGX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jul 2026 | $111.58M | -4.1% | -3.8% | 0.9% | |
| Jun 2026 | $7.3M | -2.7% | -2.5% | 0.0% | |
| Jun 2026 | $2.4M | -4.9% | -2.2% | 0.0% | |
| Sep 2026 | $2M | +0.0% | +0.0% | 0.0% | |
| Jun 2026 | $2M | +0.0% | +0.0% | 0.0% | |
| Jun 2026 | $45K | +25.0% | -98.5% | 0.0% | |
| Jun 2026 | $14K | +0.0% | +8.4% | 0.0% | |
| Sep 2026 | $8K | +0.0% | +10.1% | 0.0% | |
| Sep 2026 | $1K | +0.0% | +0.0% | 0.0% | |
| Peer median (excluding DGX) | $1.02M | +0.0% | -1.1% | 0.0% | |
Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 872M | 315M | 686M | 549M | 420M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.44B | 1.2B | 1.21B | 1.3B | 1.41B |
| Inventory | 208M | 192M | 190M | 188M | 189M |
| Other Current Assets | 187M | 196M | 286M | 351M | 361M |
| Total Current Assets | 2.74B | 1.9B | 2.37B | 2.39B | 2.38B |
| Property, Plant & Equipment (Net) | 2.3B | 2.35B | 2.42B | 2.76B | 2.86B |
| Goodwill | 7.1B | 7.22B | 7.73B | 8.86B | 8.95B |
| Intangible Assets | 1.17B | 1.09B | 1.17B | 1.76B | 1.64B |
| Long-term Investments | 141M | 132M | 135M | 123M | 136M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 163M | 144M | 198M | 255M | 270M |
| Total Non-current Assets | 10.87B | 10.94B | 11.65B | 13.76B | 13.85B |
| Total Assets | 13.61B | 12.84B | 14.02B | 16.15B | 16.23B |
| Account Payables | 357M | 324M | 378M | 287M | 1.6B |
| Short-term Debt | 269M | 247M | 585M | 937M | 678M |
| Tax Payables | 10M | 2M | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 599M | 550M | 471M | 466M | 0 |
| Total Current Liabilities | 1.75B | 1.55B | 1.82B | 2.17B | 2.28B |
| Long-term Debt | 4.01B | 3.98B | 4.41B | 5.6B | 5.7B |
| Deferred Tax Liabilities | 290M | 295M | 270M | 250M | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 502M | 517M | 606M | 688M | 420M |
| Total Non-current Liabilities | 5.3B | 5.28B | 5.79B | 7.09B | 6.66B |
| Total Liabilities | 7.05B | 6.83B | 7.6B | 9.26B | 8.94B |
| Common Stock | 2M | 2M | 2M | 2M | 2M |
| Retained Earnings | 7.65B | 8.29B | 8.83B | 9.36B | 9.99B |
| Accumulated OCI | (14M) | (21M) | (14M) | (88M) | (27M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 118M | 114M | 111M | 118M | 116M |
| Total Equity | 6.56B | 6.01B | 6.42B | 6.9B | 7.29B |
| Total Debt | 4.77B | 4.71B | 5.5B | 7.09B | 6.92B |
| Net Debt | 3.9B | 4.4B | 4.81B | 6.54B | 6.5B |
Quest Diagnostics Incorporated
NYSE:DGX
Intrinsic Alpha fair value
Locked
Current Price
$259.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.